<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001653'>Mitral regurgitation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) is the most-common <z:hpo ids='HP_0001654'>valvular heart disease</z:hpo> in the western world </plain></SENT>
<SENT sid="1" pm="."><plain>From an etiologic point of view, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> can be either organic (mainly degenerative in western countries) or functional (secondary to left ventricular remodeling in the context of ischemic or idiopathic <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>Degenerative and functional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> are completely different disease entities that pose specific decision-making problems and require different management </plain></SENT>
<SENT sid="3" pm="."><plain>The natural history of severe degenerative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> is clearly unfavorable </plain></SENT>
<SENT sid="4" pm="."><plain>However, the appropriate and timely correction of degenerative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> is associated with a life expectancy similar to that of the <z:mpath ids='MPATH_458'>normal</z:mpath> population </plain></SENT>
<SENT sid="5" pm="."><plain>By contrast, the prognostic impact of the correction of functional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> is still a matter of debate </plain></SENT>
<SENT sid="6" pm="."><plain>In this Review, we discuss the optimal treatment of both degenerative and functional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>, taking into account <z:hpo ids='HP_0000001'>all</z:hpo> presently available therapeutic options, including novel percutaneous methods </plain></SENT>
<SENT sid="7" pm="."><plain>Since a clear understanding of the etiology and mechanisms of valvular dysfunction is important to guide the timing and choice of treatment, the role of echocardiography in the management of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> is also addressed </plain></SENT>
</text></document>